Chromatography process for purification of insulin and insulin analogs
View Patent ↗A process is described for purifying insulin and insulin analogs that comprises use of two or more orthogonal chromatographic purification steps in tandem following enzymatic digestion of the propeptide-insulin precursor to remove specific product impurities, improve process consistency, and increase process redundancy in the purification of the insulin or insulin analog, e.g., insulin lispro.
1. A process for isolating properly folded insulin or insulin analog from process related impurities, wherein the process comprises:
subjecting an aqueous solution comprising properly folded precursor insulin or insulin analog that has been enzymatically digested to produce properly folded insulin or insulin analog and process related impurities to two orthogonal chromatography purification steps in tandem to separate the isolated properly folded insulin or insulin analog from the process related impurities;
wherein the two orthogonal chromatography purification steps in tandem comprise (i) a mixed mode anion exchange (MMA) chromatography step performed with a resin comprising cross-linked agarose conjugated to N-benzyl-N-methyl ethanolamine or an anion exchange (AEX) chromatography step performed with a resin comprising agarose conjugated to DEAE and (ii) an RP-HPLC step performed with a silica-based reverse phase resin in the presence of a water miscible organic modifier; and,
wherein the MMA or AEX chromatography comprises
(i) applying to the MMA or AEX chromatography matrix the aqueous solution in which properly folded precursor insulin or insulin analog has been enzymatically digested to produce the properly folded insulin or insulin analog;
(ii) washing the MMA or AEX chromatography matrix with a first wash solution comprising a buffer at a basic pH and then washing the MMA or AEX chromatography matrix with a second wash solution comprising a buffer at an acidic pH greater than or higher than the pH capable of eluting the properly folded insulin or insulin analog from the MMA or AEX chromatography matrix; and
(iii) eluting the properly folded insulin or insulin analog from the MMA or AEX chromatography matrix with an eluting solution comprising a buffer at an acidic pH sufficient to elute the properly folded insulin or-insulin analog from the MMA or AEX chromatography matrix to provide a mixture of the properly folded insulin or insulin analog for the RP-HPLC step.
2. The process of claim 1 , wherein the RP-HPLC comprises eluting the properly folded insulin or insulin analog with a linear gradient of a water miscible organic modifier.
3. The process of claim 1 , wherein the insulin or insulin analog has an isoelectric point from 4.5 to 8.5.
4. The process of claim 1 , wherein the insulin analog is insulin lispro; insulin glargine; insulin aspart; insulin glulisine, insulin, 21 A -glycine-30 B -L-arginine; insulin, 21 A -glycine; insulin 21 A -glycine-des-30 B -threonine; or insulin, des-30 B -threonine.